<DOC>
	<DOC>NCT01795690</DOC>
	<brief_summary>The purpose of this registry is to record information of routine treatment of anemia in cancer patients in Germany. An overview of the current treatment of anemia in German outpatient centers and hospitals will be provided. Primary outcome parameters, e.g. improvement in hemoglobin levels and changes in QoL, as well as patient characteristics of different treatments will be analyzed.</brief_summary>
	<brief_title>Clinical Tumor Anemia Registry (TAR)</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<criteria>Histologically confirmed malignant disease Hemoglobin level &lt; 11 g/dl (female) or &lt; 12 g/dl (male) Start of antianemic therapy no more than 7 days prior to informed consent Performance status 0 3 (KarnofskyIndex &gt;= 40%) Minimum age: 18 years Informed written consent Hypersensitivity against antianemic therapies Myelodysplastic Syndrome Experimental antianemic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Anemia</keyword>
	<keyword>Cancer</keyword>
	<keyword>Hemoglobin</keyword>
	<keyword>Quality of Life</keyword>
	<keyword>FACT-An</keyword>
	<keyword>FACT-GP</keyword>
	<keyword>Erythropoiesis-Stimulating Agents (ESA)</keyword>
	<keyword>Epoetin</keyword>
	<keyword>Ferric Carboxymaltose</keyword>
	<keyword>Blood Transfusions</keyword>
</DOC>